
Sales Effectiveness
Latest News
Latest Videos

Shorts
More News

The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.

CGT commercial trajectories are set years before approval — and every development decision is an access decision.

Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.

Inizio's Elaine Ferguson on why connecting talent across 10,500 employees and four business units is fundamental to delivering client value.

Discover how Quest Diagnostics puts its vast database of lab results to work and leverages patient and physician credibility to efficiently and effectively connect the best-fit patients to the clinical trials that will benefit from their participation.

As the clinical research landscape evolves, decentralized clinical trials (DCTs) have emerged as a foundational competency, enabling broader patient participation, increasing trial efficiency, and driving more inclusive, real-world data collection. However, the successful execution of DCTs requires more than just innovative technology—it demands a comprehensive strategy that addresses the unique challenges of decentralization.

As the clinical research landscape evolves, decentralized clinical trials (DCTs) have emerged as a foundational competency, enabling broader patient participation, increasing trial efficiency, and driving more inclusive, real-world data collection. However, the successful execution of DCTs requires more than just innovative technology—it demands a comprehensive strategy that addresses the unique challenges of decentralization.

Download the case study and learn how Quest Diagnostics and PatientsLikeMe helped accelerate recruitment and enrollment for a struggling study.

ACTO’s CEO on AI trust, the future of the sales rep, and why human intelligence plus empathetic agents is the winning formula.

A recent study of more than 15,000 adults over 55 with obesity found that sustained Zepbound use was associated with up to 38% lower monthly healthcare costs at 12 months compared with untreated matched controls.

How drug pricing, tariffs, and manufacturing decisions are becoming connected.

Eli Lilly posted $23 billion in second-quarter revenue driven by Mounjaro's sales surge to $9.94 billion and Zepbound's $4.93 billion.

Inside Pharma's Patent Battleground: The Policy Changes Reshaping Generic and Biosimilar Competition
Recent changes at the U.S. Patent and Trademark Office are making it harder to challenge pharmaceutical patents, raising concerns that slower generic and biosimilar competition could undermine efforts to lower drug costs while strengthening protections for brand-name innovators.

Two-thirds of pharmaceutical product launches fail to meet first-year commercial expectations, and the gap between launch strategy and field execution is almost always why, according to this examination of how to identify, diagnose, and correct launch drift before it becomes irreversible.

Mike Faddoul, Partner, Audit & Assurance, Crowe, makes the case that gross-to-net accounting deserves the same pre-launch rigor as commercial strategy.

The pharmaceutical industry has spent the last two years debating whether direct-to-patient pharma business models are real. That debate is over.
















